Cost competitive Oxford Pharmaceuticals operates a cost-effective manufacturing platform for generic oral solids with in-house process development and regulatory expertise, presenting a compelling value proposition for potential buyers seeking affordable high-volume generic APIs and finished dosage forms.

FDA approved capacity A modern 150,000 sq ft facility certified by the FDA since 2019 with scalable manufacturing and automated packaging line serialization aligned to 2023 requirements, enabling reliable supply for large-volume orders and potential partnerships for new generic products.

Product portfolio Launching a basket of 30+ generic products creates cross-sell and portfolio expansion opportunities for distributors and contract manufacturers looking to broaden their generic offerings and capture share in multiple therapeutic categories.

Strategic location Based in Birmingham, Alabama with private ownership and a robust warehouse footprint supports efficient distribution and warehousing of finished products, appealing to regional and national distributors seeking reliable US-based manufacturing partners.

Growth momentum Entered market during the pandemic with continuous launches and growing monthly, signaling resilience and ongoing opportunity for channel partners to co-market, co-manage inventory, and accelerate new product launches.